Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Ophthalmology Precision Panel > Optic Atrophy Precision Panel

Optic Atrophy Precision Panel

Optic atrophy is the clinical manifestation of any disease process causing axon degeneration in the retinogeniculate pathway. Particularly, these diseases affect the retinal ganglion cells and their axons forming the optic nerve, which are in charge of transferring the visual information from the photoreceptors to the lateral geniculus in the brain.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Optic atrophy is the clinical manifestation of any disease process causing axon degeneration in the retinogeniculate pathway. Particularly, these diseases affect the retinal ganglion cells and their axons forming the optic nerve, which are in charge of transferring the visual information from the photoreceptors to the lateral geniculus in the brain. Optic atrophy is clinically seen as changes in the color and the structure of the optic disc associated with variable degrees of visual dysfunction starting typically in the first decade of life. It is a relative common form of inherited optic neuropathy and it may be syndromic which can include extra-ocular symptoms mostly neuromuscular. The mode of inheritance varies from mitochondrial, autosomal dominant and recessive.  

  • The Igenomix Optic Atrophy Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of progressive blindness ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Optic Atrophy Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: 
    • Blurred vision 
    • Difficulties with peripheral vision  
    • Difficulties with color vision  
    • Reduction in the sharpness of vision

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team in the form of regular ophthalmologic examination, low vision aids and preventive measures such as avoidance of alcohol, tobacco and some medications.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 

Genes & Diseases

Methodology

References

See scientific referrals

Lenaers, G., Hamel, C., Delettre, C., Amati-Bonneau, P., Procaccio, V., Bonneau, D., Reynier, P., & Milea, D. (2012). Dominant optic atrophy. Orphanet journal of rare diseases, 7, 46. https://doi.org/10.1186/1750-1172-7-46 

Votruba, M., Moore, A. T., & Bhattacharya, S. S. (1998). Clinical features, molecular genetics, and pathophysiology of dominant optic atrophy. Journal of medical genetics, 35(10), 793–800. https://doi.org/10.1136/jmg.35.10.793 

Jones, R., Al-Hayouti, H., Oladiwura, D., Karim, R., Sawczenko, A., & Dahlmann-Noor, A. (2020). Optic atrophy in children: Current causes and diagnostic approach. European journal of ophthalmology, 30(6), 1499–1505. https://doi.org/10.1177/1120672119899378 

Chun, B. Y., & Rizzo, J. F., 3rd (2017). Dominant Optic Atrophy and Leber’s Hereditary Optic Neuropathy: Update on Clinical Features and Current Therapeutic Approaches. Seminars in pediatric neurology, 24(2), 129–134. https://doi.org/10.1016/j.spen.2017.06.001 

Vaphiades, M. S., & Brodsky, M. C. (2012). Pediatric optic atrophy. International ophthalmology clinics, 52(3), 17–xiii. https://doi.org/10.1097/IIO.0b013e31825a14ba 

Pilz, Y. L., Bass, S. J., & Sherman, J. (2017). A Review of Mitochondrial Optic Neuropathies: From Inherited to Acquired Forms. Journal of optometry, 10(4), 205–214. https://doi.org/10.1016/j.optom.2016.09.003 

 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information